A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea.
Sun Bean Kim ; Yong Chan Kim ; June Myung Kim ; Jun Yong Choi ; Young Goo Song ; Sang Hoon Han ; Su Jin Jeong ; Hye-won Kim ; Nam Su Ku ; Jin Young Ahn ; Dong Hyun Oh ; Je Eun Song ; Min Hyung Kim
Scandinavian Journal of Infectious Diseases, Vol.45(11) : 855~862, 2013
Scandinavian Journal of Infectious Diseases
Background: The introduction of highly active antiretroviral therapy (HAART) has extended the life expectancy of persons infected with the human immunodeficiency virus type 1 (HIV-1). However, cardiovascular disease (CVD) is currently an increasing concern for HIV-infected persons. Methods: We conducted a cross-sectional case–control study to evaluate and compare the 10-y cardiovascular risk of HIV-infected Koreans who had been receiving HAART for over 6 months and age- and sex-matched uninfected persons who visited a health promotion center, by calculating Framingham risk scores (FRS). Results: The average 10-y risk for cardiovascular events (FRS) was 7.07% (2–45) in the HIV group and 6.87% (1–37) in the control group (p = 0.77), corresponding to the very low risk group. Among HIV patients, the FRS was above 10% (low to moderate cardiovascular risk) in 19.9% of the patients, and above 20% (high risk) in 1.7% of the patients. In the healthy control group, the FRS was above 10% in 16.8% and above 20% in 2.7% (p = 0.57). The FRS was not significantly different for HIV-infected patients treated with protease inhibitor (PI)-based HAART and those treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (7.26 ± 6.3 and 6.81 ± 4.4, respectively, p = 0.69). Conclusions: The predicted cardiovascular risk of HIV-infected Koreans on HAART by FRS equation was low and similar to that of age- and sex-matched healthy control persons. However, the possibility remains that actual cardiovascular events could be underestimated. The next step for predicting the cardiovascular risk is to calculate the Data Collection of Adverse Events of Anti-HIV Drugs (D:A:D) equation risks.